
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Genelux Corporation Common Stock (GNLX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GNLX (1-star) is a SELL. SELL since 2 days. Profits (5.96%). Updated daily EoD!
1 Year Target Price $18
1 Year Target Price $18
3 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.59% | Avg. Invested days 23 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 128.81M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 5 | Beta -0.35 | 52 Weeks Range 1.95 - 5.88 | Updated Date 08/15/2025 |
52 Weeks Range 1.95 - 5.88 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.22 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.14% | Return on Equity (TTM) -98.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 102541440 | Price to Sales(TTM) 12362.41 |
Enterprise Value 102541440 | Price to Sales(TTM) 12362.41 | ||
Enterprise Value to Revenue 6302.51 | Enterprise Value to EBITDA -327.19 | Shares Outstanding 37773400 | Shares Floating 33302151 |
Shares Outstanding 37773400 | Shares Floating 33302151 | ||
Percent Insiders 11.4 | Percent Institutions 21.51 |
Upturn AI SWOT
Genelux Corporation Common Stock
Company Overview
History and Background
Genelux Corporation Common Stock was founded in 2005, focusing on biotechnology. Early milestones involved pre-clinical trials. They went public in 2015 and have since focused on clinical development of their oncolytic virus therapies.
Core Business Areas
- Oncolytic Virus Immunotherapy: Development and commercialization of oncolytic viruses to treat cancer. This includes preclinical and clinical development programs.
- Proprietary Platform Technology: Genelux has developed a proprietary platform for the design and engineering of oncolytic viruses.
Leadership and Structure
The leadership team consists of a CEO with extensive biotech experience, a CFO overseeing financial strategy, and a Chief Scientific Officer leading research and development. The organizational structure is functional, with departments for research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Olvi-Vec (vusolimogene oderparepvec): An oncolytic vaccinia virus designed to selectively infect and destroy cancer cells. It is currently in Phase 3 clinical trials. Market share is currently 0% as it awaits FDA approval. Competitors include companies developing other oncolytic virus therapies, such as Amgen (T-Vec).
Market Dynamics
Industry Overview
The oncolytic virus therapy market is rapidly growing, driven by increasing cancer rates and the limitations of traditional cancer treatments. The industry is characterized by intense research and development and increasing regulatory approvals.
Positioning
Genelux is positioned as an emerging player in the oncolytic virus therapy market, with a promising platform technology and a lead product in late-stage clinical development. Their competitive advantage lies in the unique properties of their oncolytic virus.
Total Addressable Market (TAM)
The global oncolytic virus therapy market is projected to reach $887 million by 2028. Genelux is positioned to capture a significant portion of this market if Olvi-Vec is approved, primarily targeting cancers with limited treatment options.
Upturn SWOT Analysis
Strengths
- Proprietary oncolytic virus platform
- Lead product in late-stage clinical trials
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Dependence on a single product
- Lack of commercialization experience
- High regulatory risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new oncolytic virus candidates
- Expansion into new cancer indications
- Positive clinical trial results
Threats
- Failure to obtain regulatory approval
- Competition from other oncolytic virus therapies
- Adverse events in clinical trials
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- AMGN
- MRTX
- BNTX
Competitive Landscape
Genelux competes with larger pharmaceutical companies that have established oncolytic virus therapies. Their competitive advantage will depend on the efficacy and safety profile of Olvi-Vec compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited to the progression of their lead product through clinical trials.
Future Projections: Future growth is highly dependent on the successful commercialization of Olvi-Vec. Analyst projections vary based on regulatory approval and market penetration.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 clinical trials and seeking partnerships for commercialization.
Summary
Genelux is a development-stage biotech company with a promising oncolytic virus platform. Their success hinges on positive Phase 3 clinical trial results and regulatory approval of Olvi-Vec. They face significant financial and competitive challenges as they compete with larger, more established players in the market. Investors need to monitor the clinical trial progress, financial runway, and competitive landscape carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data, which is subject to change. Investing in biotech companies is inherently risky, and investors should carefully consider their own risk tolerance and financial circumstances before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genelux Corporation Common Stock
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2023-01-26 | Chairman, CEO & President Mr. Thomas D. Zindrick J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.genelux.com |
Full time employees 24 | Website https://www.genelux.com |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.